ClinicalTrials.gg
Not yet recruitingNCT07018531Updated Jun 17, 2025

Vertical Soft Tissue Augmentation With Tent Pole Technique and Its Influence on Marginal Bone Loss Around Dental Implants

An interventional study of VST augmentation with TPT and TPT-PRF in Soft Tissue Augmentation Around Dental Implants, sponsored by University of Santiago de Compostela. Not yet recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-17.

Sponsored by University of Santiago de Compostela · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to evaluate the effectiveness of the tent pole technique in vertical peri-implant soft tissue augmentation and to assess its impact on marginal bone loss. Additionally, the adjunctive use of platelet-rich fibrin and photobiomodulation will be explored to determine their influence on the clinical outcomes of this procedure.

Read the detailed description

Thin vertical soft tissues (VST) around dental implants pose a clinical challenge due to their strong association with marginal bone loss (MBL). Current evidence suggests that a minimum of 3 mm of VST height is essential to ensure peri-implant bone stability. Several techniques have been proposed to augment soft tissue thickness and reduce MBL, including connective tissue grafts, membranes, platelet-rich fibrin (PRF), and the Tent Pole Technique (TPT), which uses a 2 mm healing abutment to tent the soft tissue. This randomized controlled clinical trial aims to assess the effectiveness of the TPT when performed simultaneously with implant placement, in comparison to a non-intervention control group, for vertical soft tissue augmentation. Additionally, the study evaluates the impact of two adjunctive therapies: photobiomodulation (PBM) and PRF combined with TPT. In fact, PBM involves the application of low-level laser therapy at a wavelength of 630 nm to the occlusal site immediately after surgery and again at day 7, with the goal of enhancing cellular activity, accelerating healing, and promoting soft tissue regeneration. PRF, an autologous concentrate rich in growth factors, is used to fill the space created by the healing abutment in the TPT, further supporting tissue regeneration. The study includes four groups: TPT alone, TPT combined with PBM, TPT combined with PRF, and a control group without soft tissue intervention. The hypothesis is that TPT is effective in increasing vertical soft tissue thickness and maintaining marginal bone levels, and that its combination with either PBM or PRF may further enhance clinical outcomes both in the short and long term.

02

Conditions studied

  • Soft Tissue Augmentation Around Dental Implants

Keywords

  • Dental Implants
  • Vertical Soft Tissue
  • Tent Pole Technique
  • Platelet-Rich Fibrin
  • Photobiomodulation
  • Marginal Bone Loss
03

In context

Lead sponsor

University of Santiago de Compostela is the lead sponsor of 60 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be over 18 years of age. They should be legally capable of adhering to study protocols, which include maintaining proper oral hygiene, attending all scheduled follow-up visits, fully understanding the proposed surgical procedures, and signing the form.
  • single edentulous sites in the premolar and/or molar region of the mandible.
  • Vertical gingival thickness must be more than 1 mm and less than or equal to 2 mm.
  • A minimum of 2 mm of attached gingiva should be present on both the buccal and lingual sides of the implant sites.
  • Buccal bone thickness must be at least 1.5 mm.

Exclusion criteria

Exclusion Criteria:

  • Presence of general for dental implants or surgical interventions.
  • Heavy smoking, defined as more than 10 cigarettes daily, including pipe, vape or cigar use.
  • Poor oral hygiene, characterized by probing depths greater than 4 mm in adjacent teeth, and a full mouth plaque score (FMPS) or full mouth bleeding score (FMBS) exceeding 25% after the pre-treatment phase.
  • Guided bone regeneration at the implant site.
  • History of conditions or diseases that compromise bone metabolism (e.g. Paget's disease, osteoporosis) or current use of medications that may affect bone metabolism (e.g. bisphosphonates).
  • History of cancer or prior radiotherapy or chemotherapy treatments for .
  • Uncontrolled diabetes.
  • Current pregnancy or breastfeeding status.
  • Allergies to any products involved in the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
112 participants (estimated)

Study arms

  • Experimental
    Tent pole technique

    Procedure: VST augmentation with TPT

  • Experimental
    Tent pole technique with platelet-rich fibrin

    Procedure: TPT-PRF

  • Experimental
    Tent pole technique with photobiomodulation

    Procedure: TPT-PBM

  • Experimental
    Negative control group

    Procedure: Group control: implant placement without TPT

Interventions

  • ProcedureVST augmentation with TPT

    For TPT group, vertical soft tissue augmentation will be performed simultaneously with implant placement using a 2 mm healing abutment. Than, to ensure tension-free primary closure, mucoperiosteal flaps will be mobilized through vertical releasing incisions. Wound closure will be achieved using horizontal mattress sutures, followed by simple interrupted sutures for optimal tissue adaptation. The healing abutment will act as a mechanical support to maintain space and prevent soft tissue collapse. This tented space is expected to allow blood to accumulate, clot, and gradually reorganize into connective tissue, thereby promoting an increase in vertical soft tissue thickness around the implant. After 2 months , the initial 2-mm healing abutment will be removed, and a 4 mm healing abutment will be placed by mading a small semilunar incision without touching the bone.

  • ProcedureTPT-PRF

    In the PRF group, the same surgical protocol as the TPT group will be followed. However, prior to wound closure, the tented space surrounding the healing abutment will be filled with PRF membranes.

  • ProcedureTPT-PBM

    The PBM group will follow the same surgical protocol as the TPT group. In addition, this group will receive photobiomodulation therapy using red-light irradiation at a wavelength of 630 nm, applied to the occlusal site immediately after surgery and repeated after 7 days.

  • ProcedureGroup control: implant placement without TPT

    The negative control group will consist of patients randomly selected from the recruited population, in accordance with the study's inclusion criteria. Participants in this group will not receive any intervention aimed at VST augmentation during implant placement. This will allow for a clear assessment of the effect of the TPT on VST gain and its impact on MBL. In accordance with ethical guidelines, patients in the control group will undergo VST augmentation at a second stage, prior to the initiation of the prosthetic phase.

06

What researchers measure

Primary outcomes

  1. vertical soft tissue height

    Time frame: 2 months , 4 months and 6 months

  2. Marginal BoneLoss

    Time frame: 2 months, 4 months, 6 months

Secondary outcomes

  1. PPD

    Pocket probing depth

    Time frame: 6 months

  2. BOP

    Bleeding on probing

    Time frame: 6 months

  3. PI

    Plaque Index

    Time frame: 6 months

07

Study locations

2 sites
  • Oral Medicine, Oral Surgery and Implantology Unit (Medoralres), Faculty of Medicine and Dentistry, University of Santiago de Compostela
    Santiago de Compostela, A Coruña 15782, Spain
    • Mario Pérez Sayáns, PhD, PhD, MDS, FDS, DDS · Contactmario.perez@usc.es · +34 626233504
  • Oral Health and Oral Rehabilitation Research Laboratory, LR12ES11, Faculty of Dental Medecine of Monastir, University of Monastir
    Monastir, 5019, Tunisia
08

References and documents

Individual participant data

Plan to share: Yes — data collected during our dental implant study will be made accessible to qualified researchers upon reasonable request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2025; primary completion for Jun 2026, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2025
First posted
Jun 12, 2025
StartEst.
Jul 2025
Primary completionEst.
Jun 2026
CompletionEst.
Aug 2026
Last update
Jun 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07018531
Lead sponsor
University of Santiago de Compostela
Collaborators
Galimplant Dental Implants
Responsible party
Mario Pérez Sayáns (Full Professor in Oral Medicine, Oral Surgery and Implantology, Faculty of Dental Medicine, University of Santiago de Compostela, University of Santiago de Compostela) — Principal investigator
First posted
Jun 12, 2025
Start date
Jul 2025 (estimated)
Primary completion
Jun 2026 (estimated)
Completion
Aug 2026 (estimated)
Last update
Jun 17, 2025

Study contacts

Fakhreddine Alouane, DMD, Msc, PhD candidate
Contact
alouenefakhri@gmail.com
+34 615270185

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion